Tag Archives: clinical trials

Another Ovarian Cancer Vaccine Trial Approved

MXi Pharmaceuticals has recieved approval to begin a trial for ovarian/uterine cancer. The company hopes to start enrolling patients this calendar year. See the news release here Enroll in clinical trials here

Posted in News | Also tagged , , | Leave a comment

The Annals of Extreme Surgery (NYT)

The New York Times ran an op-ed about the lack of evidence supporting heated chemotherapy (HIPEC). The article stated that while this new treatment gives patients hope, the data is not clear that it provides benefit. HIPEC is given to … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Less than One Percent of Cancer Patients Enroll in Trials

A study based on the California Cancer Registry found that less than one percent of cancer patients enroll in clinical trials. Black patients, those older than 65, those with early stage cancer or with gastrointestinal or lunch cancers were less … Continue reading 

Posted in News | Leave a comment

PAPR Inhibitors May Work Against More Ovarian Cancers

PAPR inhibitors, first used in trials for women with ovarian cancer who had a mutation in the BRCA1 or BRCA2 gene, are now being used in trials for women without these genetic mutations and showing some effect. In a recent … Continue reading 

Posted in News | Also tagged , , , , , | Leave a comment

Drug Combination to Treat Cancer Expected to Rise

According to an article in the Wall Street Journal, combinations of drugs to treat cancer will be used more frequently in the future. Many studies presented at the 2011 annual meeting of the American Society of Clinical Oncology explored the … Continue reading 

Posted in News | Also tagged , , , | 1 Comment

Carbo/Doxil in elderly patients

BACKGROUND: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients <70 years. PATIENTS AND METHODS: Nine hundred and seventy-six patients with … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Phase II Trial of Phenoxodial Complete

INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we determined the safety and efficacy of intravenous phenoxodiol in combination … Continue reading 

Posted in News | Also tagged , , | Leave a comment

ESAs Linked to Ovarian Cancer Mortality (Medpage)

A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs (erythropoetin stimulating agents) are used to promote the growth of … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations

A new study shows that ovarian cancer patients who had the non-Askenazi Jewish BRCA mutation had longer Progression Free Surivival time and Overall Survival times than ovairan cancer patients who did not have any BRCA mutations.  See abstract here

Posted in News | Also tagged , | Leave a comment

Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released

Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial.  See the company’s release here

Posted in News | Also tagged , | Leave a comment

New clinical trial to determine ovarian cancer risks in African-American women

University Hospitals Case Medical Center and Case Western Reserve University School of Medicine are conducting an important new study addressing the lack of knowledge about causes and risk factors for ovarian cancer in African American women. The five-year study is … Continue reading 

Posted in News | 1 Comment

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. Patients and methods: Patients with ovarian cancer that had … Continue reading 

Posted in News | Also tagged , | Leave a comment